Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Bullboard - Stock Discussion Forum Jasper Therapeutics Inc JSPR

Healthcare Biotechnology

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk... see more

Add To Watchlist

Bullboard (NDAQ:JSPR)

View:

Post by PressReleaseon Feb 17, 2023 8:20am

New Press Release - Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

Post by PressReleaseon Feb 17, 2023 8:10am

New Press Release - Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days100% total donor chimerism was achieved through six months for the first patient and through three months for the second patientBoth patients are doing well post-transplant with...read article.

Largest Integrated Facility Services Provider in Canada Releases Financial Results for Q1, 2025

posted May 11, 2025 9:00am by GDI Integrated Facility Services Inc.

Adjusted EBITDA* amounted to $34 million, representing an Adjusted EBITDA* margin of 6% compared to $28 million and 4% in Q1 2024. Net income was $6 million or $0.26 per share compared to $0.4 million or $0.02 per share in Q1 2024.Long-term debt, net of cash* decreased by $14 million in the quarter ...read more

Post by PressReleaseon Feb 17, 2023 8:00am

New Press Release - Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Oral Presentation, Abstract #59: 12 out of 12 AML in complete remission patients with full 1-year follow-up achieved successful neutrophil engraftment at a median of 19 days after conditioning with briquilimab in combination with fludarabine and low dose irradiation Oral Presentation...read article.

Post by PressReleaseon Feb 16, 2023 4:05pm

New Press Release - Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients

Data Presented in Plenary Session at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-upThird sickle cell disease participant has now achieved 100% donor...read article.

Post by PressReleaseon Feb 03, 2023 4:05pm

New Press Release - Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

Post by PressReleaseon Jan 30, 2023 8:00am

New Press Release - Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023

REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

Post by PressReleaseon Jan 27, 2023 1:10pm

New Press Release - Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

Post by PressReleaseon Jan 25, 2023 8:00am

New Press Release - Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

Post by PressReleaseon Jan 24, 2023 4:26pm

New Press Release - Jasper Therapeutics Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk...read article.

Post by PressReleaseon Jan 13, 2023 8:00am

New Press Release - Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Three abstracts highlight the safety and efficacy of briquilimab combined with low-toxicity radiation conditioning to achieve full donor engraftment and leukemia disease eradication Data demonstrates that briquilimab is safe and well-tolerated as a conditioning agent in older patients, median...read article.

Post by PressReleaseon Jan 10, 2023 8:00am

New Press Release - Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases

REDWOOD CITY, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies and stem cell transplant conditioning agents targeting c-Kit, today announced, as part of an overall portfolio...read article.

Post by PressReleaseon Jan 04, 2023 8:00am

New Press Release - Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic cell transplant (HCT) therapies, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal...read article.

(103)
•••

Post by Iseneschalon Jan 03, 2023 12:03pm

JSPR ..... I see dead people !!!!

Not me ; )

110

(103)
•••

Post by Iseneschalon Jan 03, 2023 11:51am

JSPR..... Hmmmmm

EDGAR Entity Landing Page (sec.gov)

103

(103)
•••

Post by Iseneschalon Jan 03, 2023 11:17am

JSPR..... That's it for me

Wrong side of this trade 2 x's..... LoL Going else where Cheers !

85

Market Update

{{currentVideo.title}} {{currentVideo.relativeTime}}

A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}

{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}

{{currentVideo.headline}}

{{currentVideo.link1Text}}

{{currentVideo.link2Text}}

< Previous

{{moreVideoText}}

Next >

Dealroom for high-potential pre-IPO opportunities